We are live on ! Find out more
PM

Prosight Management Portfolio holdings

AUM $610M
1-Year Est. Return 40.86%
This Fund
S&P 500
This Quarter Est. Return
+6.58%
1 Year Est. Return
+40.86%
3 Year Est. Return
+46.17%
5 Year Est. Return
+1.2%
10 Year Est. Return
–
AUM
$160M
AUM Growth
+$37.8M
Cap. Flow
+$32.6M
Cap. Flow %
20.39%
Top 10 Hldgs %
54.86%
Holding
54
New
17
Increased
15
Reduced
14
Closed
8

Top Buys

Rank Stock Value
1
HAE icon
Haemonetics
HAE
+$9.48M
2
XCUR icon
Exicure
XCUR
+$5.81M
3
CNVY
Convey Health Solutions Holdings, Inc.
CNVY
+$4.75M
4
KALV
KalVista Pharmaceuticals
KALV
+$4.74M
5
RCM
R1 RCM Inc. Common Stock
RCM
+$4.15M

Top Sells

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$6.04M
2
PRTA icon
Prothena Corp
PRTA
+$5.55M
3
AUPH icon
Aurinia Pharmaceuticals
AUPH
+$2.94M
4
INOV
Inovalon Holdings, Inc. Class A Common Stock
INOV
+$2.45M
5
VRTX icon
Vertex Pharmaceuticals
VRTX
+$2.35M

Sector Composition

Rank Sector Weight
1 Healthcare 94.83%
2 Industrials 2.39%
3 Energy 1.24%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TVRD
51
Tvardi Therapeutics
TVRD
$23.5M
– –
-2,778
Closed -$2.17M
ODT
52
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
– –
-117,621
Closed -$402K
INOV
53
DELISTED
Inovalon Holdings, Inc. Class A Common Stock
INOV
– –
-85,000
Closed -$2.45M
ALXN
54
DELISTED
Alexion Pharmaceuticals
ALXN
– –
-8,685
Closed -$1.33M
1 2
3

Similar funds

PL
Pandi LLC Leawood, Kansas $610M AUM 14.97% 1-Year Est. Return
BFC
Blue Fin Capital Warren, Rhode Island $610M AUM 26.46% 1-Year Est. Return
DCM
DGS Capital Management Jersey City, New Jersey $609M AUM 44.78% 1-Year Est. Return
SAM
Strategy Asset Managers Pasadena, California $609M AUM 32.56% 1-Year Est. Return
CBB
Citizens Business Bank Ontario, California $610M AUM 27.86% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
FFWA
FRG Family Wealth Advisors Bellevue, Washington $611M AUM 25.92% 1-Year Est. Return
CIP
Convergence Investment Partners Palm Beach Gardens, Florida $611M AUM 61.48% 1-Year Est. Return

Prosight Management's Q2 2021 Portfolio in Review

As of Q2 2021, Prosight Management held 54 positions worth $160M, up 31% from $122M the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Prosight Management deployed $32.6M of net new capital in Q2 2021, opening 17 new positions and adding to 15 existing holdings. Its largest new stake was Haemonetics: 134,000 shares worth $8.93M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 96% a quarter earlier, followed by Industrials and Energy.

On the sell side, the largest reduction was Prothena Corp, an estimated $5.55M trimmed.

  • Prosight Management's largest Q2 2021 buy was Haemonetics: 134,000 shares worth $8.93M.
  • Prosight Management added most to Exicure in Q2 2021, an estimated $5.81M increase.
  • Prosight Management's biggest Q2 2021 reduction was Prothena Corp, cutting an estimated $5.55M.
  • Prosight Management fully exited Bristol-Myers Squibb in Q2 2021, selling an estimated $6.04M.
  • Prosight Management's ten largest holdings make up 55% of its $160M portfolio in Q2 2021.
  • Prosight Management opened 17 new positions and closed 8 in Q2 2021.
  • Prosight Management's portfolio value rose 31% quarter-over-quarter to $160M.

Based on Prosight Management's 13F filing for Q2 2021, filed 13 Aug 2021.